A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Inclusion Criteria:

- Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or
for which no standard therapy is available

- Previously treated metastatic triple negative breast cancer that expresses Notch3 with
at least one measurable lesion

- Adequate bone marrow, renal and liver function

Exclusion Criteria:

- Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of
starting study treatment

- Patients with known symptomatic brain metastases requiring steroids

- Prior treatment with a compound of the same mechanism